

Review

Not peer-reviewed version

Preeclampsia and the Antiphospholipid Syndrome

[Karoline Mayer-Pickel](#)^{*}, Manurishi Nanda, [Maja Gajic](#), Mila Cervar-Zivkovic

Posted Date: 26 June 2023

doi: 10.20944/preprints202306.1785.v1

Keywords: obstetric antiphospholipid syndrome; preeclampsia; prematurity; alternative therapy ; vita-min D; curcumin; hydroxychloroquine



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Preeclampsia and the Antiphospholipid Syndrome

Karoline Mayer-Pickel *, Manurishi Nanda, Maja Gajic and Mila Cervar-Zivkovic

Department of Obstetrics, Medical University Graz, Austria

* Correspondence: karoline.pickel@medunigraz.at

Abstract: Antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis and/or adverse pregnancy outcome in the presence of persistent laboratory evidence of antiphospholipid antibodies (aPL). Preeclampsia (PE) complicates about 10-17% of pregnancies with APS. However, only early onset PE (< 34 weeks of gestation) belongs to the clinical criteria of APS. The similarities in the pathophysiology of early onset PE and APS emphasize an association of these two syndromes. Overall, both are the result of a defective trophoblast invasion and decidual transformation at early gestation. Women with APS are at increased risk for prematurity; the reasons are mostly iatrogenic due to placental dysfunction, such as PE or FGR. Interestingly, women with APS have also an increased risk for preterm delivery, even in the absence of FGR and PE and therefore not indicated but spontaneous. The basic treatment of APS in pregnancy is low-dose-aspirin and low-molecular-weight-heparin. Nevertheless, up to 20-30% of women develop complications at early and late gestation despite basic treatment. Several additional treatment options have been proposed, with Hydroxychloroquine (HCQ) being one of the most efficient. Additionally, nutritional interventions, such as intake of vitamin D have shown promising beneficial effects. Curcumin, due to its antioxidant and anti-inflammatory properties, might be considered as additional intervention as well.

Keywords: obstetric antiphospholipid syndrome; preeclampsia; prematurity; alternative therapy; vitamin D; curcumin; hydroxychloroquine

1. Introduction

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the presence of antiphospholipid antibodies/aPl (anticardiolipin antibodies/ACLA, lupus anticoagulant/LA and anti- β 2-glycoprotein/anti- β 2-GPI). These antibodies are associated with arterial and/or venous thromboses and with various complications in early and late pregnancy (1, 2).

APS occurs as primary APS (PAPS) or as secondary APS (SAPS) when combined with other autoimmune diseases such as systemic lupus erythematosus (SLE) (3, 4).

Patients with solely obstetric complications but without any thrombotic events in the past are described as patients with obstetric antiphospholipid syndrome (OAPS) (5, 6). Clinical manifestations of OAPS are complications in early and late gestation, including recurrent early fetal loss before 10 weeks of gestation, late fetal loss at or beyond 10 weeks of gestation or placental dysfunction in second and third trimester, such as fetal growth restriction, preeclampsia or fetal death (1, 2).

Recurrent (early) fetal loss is with a prevalence of up to 40% the main clinical manifestation of OAPS (7); on the other hand, 20% of all women with recurrent fetal loss are tested positive for at least one antiphospholipid antibody (aPl) (8).

Late fetal loss and intrauterine fetal death (IUFD) are rather rare pregnancy complications in women with APS. Nevertheless, a significant association of IUFD and aPl could be detected in up to 14% of cases (9-11).

Fetal growth restriction (FGR) is usually defined as an estimated fetal weight (EFW) or an abdominal circumference (AC) <10th percentile for gestational age (12).

It is associated with an increased risk of perinatal morbidity and mortality as well as impairment of long-term outcome (13); additionally, the rate of preterm delivery is significantly higher in fetuses with impaired fetal growth (14).

Preeclampsia (PE) is a pregnancy-specific multiorgan disorder, complicating 3-5 % of all pregnancies (15). PE is diagnosed based on a new onset of hypertension and proteinuria or end organ damage after 20 weeks of gestation (15). It presents itself in two different phenotypes, depending on onset of symptoms as well as clinical manifestation (15). Early onset of PE/EOP occurs before 34 weeks of gestation, late onset PE/LOP after 34 weeks of gestation (15).

EOP is usually associated with fetal growth restriction and is considered the more "severe" form, whereas LOP usually is characterized by solely maternal manifestation and features a mild to moderate manifestation (16).

Prematurity is defined as a birth that occurs before 37 completed weeks of gestation (17). It is associated with an increased neonatal morbidity and mortality, particularly among extremely preterm infants (<28 weeks) (17).

It is a known fact that women with APS have an increased risk of developing PE (18); in these instances, PE is often severe and sometimes occurs even at mid-trimester (18-23).

However, only preeclampsia, nay prematurity occurring before 34 weeks of gestation is considered a bona fide manifestation of "classic" OAPS. When developing after 34 weeks of gestation, the Sydney criteria are not fulfilled and the term "aPl- related obstetric morbidity" (OMAPS) or non-criteria APS (NC-OAPS) should be used instead (5). Other criteria of OMAPS are i.a. "only" two consecutive early fetal losses, at least two non-consecutive fetal losses or premature rupture of fetal membranes (5).

The basic treatment of APS in pregnancy is low-dose-aspirin (LDA) and low-molecular-weight-heparin (LMWH). Nevertheless, up to 20-30% of women develop complications at early and late gestation despite basic treatment (24). Interestingly, the efficacy of treatment is lower for the prevention of late pregnancy complications such as PE or other forms of placental dysfunction compared to complications at early gestation such as recurrent fetal loss (25). Several additional treatment options have been proposed, with Hydroxychloroquine (HCQ) being one of the most efficient (26-29).

Additionally, nutritional interventions, such as intake of vitamin D have shown promising beneficial effects (30-34).

However, little is still known about the relationship of PE and APS. Especially, does prematurity occur without PE or other forms of placental dysfunction? Does late onset preeclampsia in women with APS (or aPl positive women) even exist? If so, should the Sydney criteria be adapted? And, are there any other additional treatment options?

The answers to these questions are the focus of this review.

2. Discussion

Strictly speaking, PE is not an actual diagnostic criterion for APS, but prematurity before 34 weeks of gestation is (1). Reasons for prematurity, respectively preterm delivery are mostly iatrogenic due to placental dysfunction, such as PE or FGR (1).

PE is defined as increased blood pressure de novo or superimposed on chronic hypertension (systolic > 140 and/or diastolic > 90 mmHg) and one or more of the following: proteinuria [spot urine protein/creatinine [30 mg/mmol (0.3 mg/ml) or [300 mg/day or at least 1 g/l ('2+') on dipstick testing], other maternal organ dysfunction or uteroplacental dysfunction with FGR (35).

PE presents itself in two different phenotypes, depending on onset of disease (16, 36-38). EOP (< 34 weeks of gestation) is characterized by fetal (i.e. fetal growth restriction/FGR) and maternal manifestation, whereas in LOP (> 34 weeks of gestation) maternal symptoms occur mostly alone (16). Although EOP is often considered the more severe form and LOP is characterized by "only" mild to moderate manifestations, the importance of the consequences in both forms after delivery should not be underestimated.

2.1. Association of APS and PE

The first relationship between aPI, nay, lupus anticoagulant and complications in pregnancy was described in 1980 by Firkin BG et al (39). Three years later a detailed clinical description of a new autoimmune syndrome- the antiphospholipid syndrome- was published for the first time by Graham Hughes (40); An association of lupus anticoagulant and PE, respectively FGR was mentioned by Branch DW in 1985 (41). Due to a rather high rate of PE in women with aPI, a first possible relationship of PE and aPI has therefore been described by various authors (41-45).

2.1.1. Pathophysiology of APS and PE

The similarities in the pathophysiology of early onset PE and APS emphasize an association of these two syndromes. Overall, both are the result of a defective trophoblast invasion and decidual transformation at early gestation.

The “two-hit” hypothesis is considered the most relevant explanation of the development of clinical manifestations of APS: aPI (“first hit”) cause a pro-coagulant phenotype by cell activation (i.a. platelets, monocytes, endothelial cells), activation of the anticoagulant and fibrinolytic system as well as enhanced inflammation, especially activation of the complement system. This pro-thrombotic state leads to thrombosis (“second hit”) in the presence of an additional factor or trigger (46). However, the “two-hit” assumption does not fully explain the pathogenesis of the various obstetric manifestations in APS (47). According to literature, aPI have a direct effect on trophoblast cells, leading i.a. to enhanced apoptosis, defective proliferation and decreased angiogenesis as well as a negative effect on transformation of spiral arteries and on maturation and differentiation of maternal decidual endometrial cells (46, 48, 49).

It is a known fact, that PE is not a single disease, but rather a syndrome, affecting many organs and is characterized by endothelial dysfunction. Although the exact mechanisms are still unknown, several systemic processes have been proposed and are meanwhile well accepted: angiogenic imbalance, oxidative stress and exaggerated systemic inflammation, all resulting in syncytiotrophoblast stress, thus leading to maternal (and placental) syndrome (15, 50-53).

PE has been proposed a two-step disease (54). The first step, starting at early gestation is characterized by an abnormal trophoblastic invasion with an impaired uterine spiral artery remodeling leading to placental oxidative stress with hypoxic injury. Systemic and excessive inflammatory processes lead to an increased secretion of pro-inflammatory cytokines, subsequently to an angiogenic imbalance with an increase of anti-angiogenic factors and a decrease of pro-angiogenic factors in the maternal circulation; this first step is asymptomatic. Especially the angiogenic imbalance seems to provoke the multisystem endothelial dysfunction leading to the specific clinical features, the second and symptomatic step of preeclampsia after 20 weeks of gestation (55).

EOP and LOP do not differ only in onset and type of clinical manifestations, but also - for the most part - in the pathophysiological mechanisms. After the abnormal trophoblastic invasion at early gestation, the “stressed” syncytiotrophoblast releases i.a. pro-inflammatory cytokines, anti-angiogenic agents, and cell-free fetal DNA, into the maternal circulation leading to a systemic inflammatory response (56, 57). In EOP, mainly the defective remodeling of the uterine spiral arteries is responsible for the uteroplacental malperfusion (58). In LOP, the maternal perfusion is normal, but pre-pregnancy constitutional/metabolic factors, especially obesity, arterial hypertension, metabolic syndrome and maternal age play a major role in the pathophysiological pathways (59, 60).

In a nut-shell, late onset PE seems to be caused by an impaired pre-pregnancy cardiovascular or metabolic status (59).

2.1.2. Prevalance of aPI in women with PE

Recurrent abortions are the most common complications of OAPS; PE occurs much less. A significant association of aPI and recurrent abortions as well as late fetal loss and IUFD could be detected in various studies (8-11). In contrast, there is a huge difference regarding the association of

APS and PE and the association of (only) aPI and PE; 20-50% of women with APS will develop PE, in the majority of cases severe PE, whereas "only" up to 10% of women with PE will test positive for aPI (41-45, 61, 62).

Additionally, the prevalence of PE in women with APS differ according to diverse authors (7, 63-65).

Clark EA et al. aimed to reveal an association of aPI and PE in the absence of other clinical criteria of APS (18). The authors could not find a relationship between PE and aPI in the general population as well as in women at risk for PE; nevertheless, women who meet the (clinical and laboratory) criteria of APS are at high risk for developing PE (18). According to the authors, testing for aPI in women who developed early onset PE can be considered; on the other side, testing in women who suffered from late onset PE is not recommended (18).

Other authors revealed different results, thus confirming an increased risk of PE already in women with aPI, but without classic APS (66-71). Heilmann L et al. analyzed blood samples from women with PE (EOP and LOP) and compared the results with women after uncomplicated pregnancy (72). 20% of women with EOP were positive for at least one aPI, whereas aPI were present in 6% of women with LOP and in 3% of women with uncomplicated pregnancies (72). According to these results, testing for aPI can also be recommended in women with PE after 34 of gestation (72).

Marchetti T. et al. analyzed plasma samples from 199 women with "non-severe" PE and from 143 women with severe PE, as well as from 195 control women (73). The authors aimed to determine an incidence of aPI in women with PE, "non-severe" and severe. Only in women who developed severe PE, an association with aPI could be detected (73).

In conclusion, the prevalence of aPI in PE is not well established yet (5).

2.2. Clinical phenotypes of OAPS

The EUROAPS, an european registry aimed to analyze the clinical features, laboratory data and pregnancy (maternal and fetal/neonatal) outcome in a cohort of 1000 women with OAPS (7). The most prevalent obstetric complications were recurrent miscarriages (38.6%), followed by fetal loss (25.3%), prematurity (28.5%) and stillbirth (23%).

EOP could be seen in 18.1% of all cases; LOP was present in 4.6% (7).

Cervera R et al. observed 1000 patients with APS over a 10-year time period (74).

Prematurity occurred in 48.2% of all live births and FGR could be detected in 26.3%. PE was present in only 6.4% (74).

Interestingly, the authors noted that the prevalence of PE decreased from the first 5 years to the last 5 years from 7.6% to 4.8%. It might be speculated that this phenomenon might be due to a better understanding of the disease and especially an improved management during pregnancy over time (74).

Another - more recent - work from the same authors investigated several clinical and immunological manifestations in a cohort of 1000 patients with - bona fide - APS in order to define a probable pattern of the disease expression (64). 71.9 % of all included women in the study were at least one time pregnant. The most common obstetric complication was early fetal loss (35.4%) followed by late fetal loss (16.9%), Prematurity occurred in 10.6%, PE in 9.5%, eclampsia in 4.4% and placental abruption in 2% (64).

2.2.1. spontaneous preterm delivery

Interestingly, women with APS have also an increased risk for preterm delivery, even in the absence of FGR and PE and therefore not indicated but spontaneous.

Yang J et al. aimed to analyze - apart from obstetric outcome - risk factors which are associated with pregnancy morbidity in women with APS (75). The authors revealed a significant higher rate of PE, as well as premature rupture of fetal membranes and postpartum hemorrhage in women with APS compared with the control group (75).

The NOH-APS (Nimes Obstetricians and Hematologists Antiphospholipid Syndrome) study analyzed the pregnancy outcomes among women with APS but without history of thrombosis and

compared the prevalence of complications during new pregnancies between treated women with APS and women negative for aPI (controls) (25). The authors revealed that among women with APS, fetal loss in a prior pregnancy was a risk factor for PE and premature birth (25).

A similar observation was made by Deguchi M. et al. (76). This multicenter study aimed to investigate the clinical features of APS-complicated pregnancies and to reveal an association of certain clinical factors with adverse pregnancy outcome. Beside thrombocytopenia and positive tests for two or more aPI, recurrent miscarriages in a previous pregnancy were independent risk factors for premature delivery before 34 weeks of gestation (76).

Other authors revealed similar results (7, 64, 65, 74, 77-79).

A dysbalance of angiogenic and anti-angiogenic factors, which is typical for pregnancy complications characterized by placental dysfunction such as PE, FGR or even fetal death, might even occur in a subset of women with spontaneous preterm labour and lacking sign of PE (80). It seems that angiogenic factors participates in the pathophysiology of preterm labour in some patients.

Based on all these findings, transvaginal ultrasound measurement of cervical length should therefore be incorporated into the therapeutic concept in women with APS, especially with prior fetal loss, even when they are asymptomatic (i.e. without spontaneous regularly occurring preterm labour).

In singleton pregnancies, the median cervical length measured before 22 weeks of gestation using transvaginal ultrasound is > 40 mm; between 22 and 32 weeks of gestation the median cervical length is approximately 40 mm and after 32 weeks of gestation about 35 mm (12, 81).

A cervical length < 25 mm is considered shortened, if the measurement (with transvaginal ultrasound) is performed before 34 weeks of gestation (82).

Primary prevention in the subsequent pregnancy consists of administration of progesterone from 16 weeks until 36 weeks of gestation (orally 200-400 mg/daily or vaginally 100-200 mg/daily) (83-87), as well as the placement of a cerclage with total closure of the cervix, carried out at the beginning of second trimester (about 15 weeks of gestation) (88-91).

2.3. Thinking outside the box

The Sydney criteria of the "classical" OAPS contain at least three consecutive early fetal losses before 10 weeks of gestation, at least one "late" fetal loss after 10 weeks of gestation and at least one stillbirth or prematurity before 34 weeks of gestation due to PE, eclampsia and/or placental insufficiency (fetal growth restriction/FGR) (1).

However, many cases do not fulfill the criteria and are classified as "aPI- related obstetric morbidity" (OMAPS), "non- criteria OAPS" (NC-OAPS) or "sero-negative" APS (SNAPS) (5, 6, 92-96).

Cases with incomplete clinical or laboratory data are classified as OMAPS or NC-OAPS, whereas SNAPS describes an entity with lacking clinical criteria but fulfilled laboratory criteria (93, 94, 96, 97).

OMAPS is defined by 1. (only) two consecutive early fetal losses before 10 weeks of gestation, 2. at least three **non**-consecutive early fetal losses before 10 weeks of gestation, 3. preeclampsia/eclampsia **after** 34 weeks of gestation (late onset preeclampsia), 4. placental abruption, 5. preterm delivery **after** 34 weeks of gestation (late preterm delivery), 6. Premature rupture of fetal membranes (PROM) and 7. unexplained recurrent implantation failure in vitro fertilization (failure of at least 3 embryo transfers of good embryo "quality") (5).

2.4. Sequela of preeclampsia, respectively prematurity

It has been demonstrated that complications at early and late gestation have lifelong health consequences for both, mother and child (98).

PE is associated with serious and especially long-term maternal and neonatal complications: for the child due to (iatrogenic) preterm delivery as well as fetal growth restriction (FGR) and for the mother an increased risk of cardiovascular morbidity and mortality, which was already described in 1964 by Epstein (99).

According to literature, 30% of women with PE develop an arterial hypertension and 25 % a metabolic syndrome

(100, 101). Structural and functional cardiovascular changes were found in women 1 year after preeclamptic pregnancies (102). Additionally, PE is associated with several chronic renal disorders in later life (103).

It has also been suggested that PE might result in a deterioration to the quality of life and increase the risk of postpartal depression (104, 105). Poel et al revealed in their work from 2009, that 1/5 of all women with PE are in need of psychological treatment several years after delivery (106).

Fetal growth restriction (FGR) is associated with substantive perinatal morbidity and mortality rates. Fetal death, periparturient asphyxia, meconium aspiration, neonatal hypoglycemia and hypothermia are all increased, as is the prevalence of abnormal neurological development (107, 108). Additionally, FGR is associated with an increased risk of cardiovascular disease and the related disorders, hypertension, stroke, and type-2 diabetes, later in life (109) (110, 111).

Premature birth is defined as delivery at less than 37 weeks of gestation and is a significant cause of infant and child morbidity and mortality, especially when occurring before 28 weeks of gestation (112).

Approximately 65% of preterm births are due to spontaneous preterm labour or preterm rupture of fetal membranes (PROM); the remaining are indicated due to maternal and/or fetal reasons (113).

Approximately two-thirds of perinatal mortality and half of long-term neurologic disabilities, such as cerebral palsy, are associated with preterm delivery (114). It also accounts for the increasing numbers of intergenerational non-communicable diseases (112).

2.5. Management of "classic APS"

The gold standard treatment is low dose aspirin (LDA; 100-150 mg/day) and low-molecular-weight-heparin (LMWH) in prophylactic dosage, starting as early as possible in pregnancy (2). Some authors recommend a start with LDA already before conception and with LMWH from the moment of positive pregnancy test (115).

However, up to 20-30% of women develop complications at early and late gestation despite treatment with LDA and LMWH. Interestingly, the efficacy of treatment is lower for the prevention of late pregnancy complications such as preeclampsia or other forms of placental dysfunction compared to complications at early gestation such as recurrent fetal loss (116, 117).

Although EOP can be prevented by the use of LDA in most cases, when started before 16 weeks of gestation, this unfortunately does not apply to LOP. "Life-style modification", such as optimizing prepregnancy weight might be a promising approach (59).

Regarding OMAPS, NC-OAPS and SNAPS, there is still debate about the management during pregnancy (5).

2.6. Management of refractory APS

Options for the prevention of recurrent fetal loss in women refractory to LDA and LMWH include low-dose prednisolone (117) as well as the use of intravenous immunoglobulins (27, 118-125), hydroxychloroquine/HCCQ (27, 126-133), plasma exchange (26, 27, 134-136), statins (5, 137, 138) or even biologics, such as TNF-alpha blockers (139, 140).

There is limited evidence on the prevention and the optimal treatment of women with aPL-associated complications at second and third trimester, such as PE. Van Hoorn ME et al. aimed to reveal a difference in obstetric outcome in aPL-positive pregnant women with recurrent hypertensive disorders of pregnancy such as PE and a previous delivery with hypertensive disorders and/or small-for-gestational-age birthweight before 34 weeks of gestation who were treated with LMWH and LDA compared to LDA alone. The authors could not show a benefit of LMWH (141). The TIPPS trial, a multicenter trial of 292 women with different thrombophilic diseases investigated the efficacy of dalteparin versus no dalteparin in the prevention of i.a. adverse obstetric outcome such as PE, placental abruption or FGR. The study showed that the prophylactic use of dalteparin did not reduce the occurrence of these complications in late pregnancy (142).

A meta-analysis described the effect of low-molecular-weight-heparin (LMWH) in pregnancies without thrombophilia for secondary prevention of PE and fetal growth restriction (FGR). The

authors revealed that the overall use of LMWH was associated with a risk reduction of PE and FGR; the use of dalteparin is associated with a risk reduction for PE and FGR, while the use of enoxaparin is only associated with a risk reduction for PE but not FGR. In conclusion, the authors found a modest beneficial effect of LMWH for secondary prevention of PE and FGR (143).

2.6.1. Hydroxychloroquin

HCQ is widely used in the prevention and treatment of different autoimmune diseases, such as systemic lupus erythematosus (144), rheumatoid arthritis (145), and Sjögren's syndrome (146-148). Several studies (126, 149-151) have provided evidence confirming the safety of HCQ during pregnancy. The positive effect in treatment of APS and reduction of PE by HCQ has been shown in few retrospective studies and *in vitro* experiments. Three retrospective studies connected HCQ with increase live birth in APS patients (130, 151, 152). The first one was done by Mekinian et al. and it involved 14 patients with refractory obstetrical APS who were additionally taking HCQ. As a result, they have observed an increase in live births in 78% of patients (130). Another retrospective study by Sciascia et al. and Gerde et al. also associated HCQ treatment with higher rate of live births (67%) as well as with a prolongation of pregnancy duration (151, 152). It has been shown that HCQ lowers the incidence of thrombosis in patients with primary APS (PAPS) (153, 154). Moreover, HCQ use was also linked to reductions in IgG anti-cardiolipin, IgG/IgM anti- β 2-glycoprotein (153, 154) and type I interferon scores (155) in patients with PAPS.

Meta-analysis found association between lower risk of PE and HCQ in SLE patients (156, 157) but not in aPI/APS patients (157). Contrary to that, Latino et al. showed that high-risk APS patients treated with HCQ had a significantly lower rate of severe early onset PE compared to those treated without HCQ (158). Moreover, Sciascia found out that APS pregnant patients who received HCQ in addition to standard therapy had lower prevalence of placenta-mediated complications, including PE (151). Due to that, four prospective clinical trials focused on APS and HCQ (HYPATIA (133), HYDROSAPL (132), HIBISCUS Belizna (131) and BBQ study (159) and two focus on PE and HCQ ([NCT04755322](#) and [NCT05287321](#)) are currently ongoing. These ongoing studies aim to further evaluate the efficacy and safety of HCQ in the management of APS and PE.

2.7. Supplementation as potential additional treatment?

Several additional attempts have been proposed; folic acid supplementation, calcium and Vitamin D being some of them (5, 160).

2.7.1. Vitamin D

A role of vitamin D deficiency in the development of autoimmune diseases has been proposed by various authors (161).

According to literature, vitamin D supplementation is associated with an improvement of inflammatory properties, immunological function as well as a reduction in antibodies (162).

This observation is supported by population-based studies (163-165). Increased activity of regulatory T cell (Tregs), a subset of T lymphocytes, and decreased proinflammatory (CD4+IL-17AT) cells are observed during vitamin D supplementation, thus leading to an anti-inflammatory T cell profile (166). Treg cells are important in repressing cytotoxic T cells, Th1 cells, macrophages, DC and NK cells leading to immune quiescence during implantation (167). Thus, vitamin D acts as a natural immune modulator (168).

The modulation functions of vitamin D on adaptive immune cells by increasing the production of IL-1-beta and IL-8 in macrophages and neutrophils is well known. Interestingly, the phagocytic ability of these cells was found to be suppressed due to Vitamin D (169). This may explain the significant association between vitamin D deficiency and autoimmune diseases, such as systemic lupus erythematosus (SLE) and APS (30, 32, 161, 163, 170-175).

Although vitamin D deficiency is commonly found in pregnant women (176), adverse pregnancy outcomes such as preeclampsia or FGR are still associated with lower levels of vitamin D during pregnancy (177).

According to literature, vitamin D deficiency in OAPS is as high as 50% (178); it is also associated with adverse pregnancy outcomes such as placental dysfunction (179).

Cyprian et al. aimed to describe a correlation between vitamin D levels and fertility, pregnancy outcomes as well as marker of APS-disease activity – namely the presence of flares and complement C3 consumption. The authors revealed that 80% of patients had low vitamin D levels and that 23 % of women with hypovitaminosis developed PE. There were no cases of preeclampsia in women with normal vitamin D levels. Additionally, vitamin D levels below 30 ng/mL were associated with complement activation and a higher incidence of flares (32).

Whether Vitamin D supplementation in OAPS is able to modulate inflammatory and immunological function and thus improves disease severity, is still unclear.

But, given the described pathophysiological changes in OAPS and the beneficial effects of vitamin D supplementation in modulating the immune system by preventing inflammation, and therefore contributing to the protection of maternal and fetal health, as well as the numerous clinical benefits, vitamin D supplementation in OAPS patients is recommended, even though there are still no controlled randomized trials.

2.7.2. Curcumin

Curcumin (*1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione*), is the main natural polyphenol present in turmeric (180). It has been used for medical reasons for approximately 4000 years due to its antimicrobial (181, 182), antioxidant and anti-inflammatory properties (183-185). Furthermore, it has been proposed that turmeric has several beneficial effects in metabolic syndrome (186), as well as diabetes mellitus and seems to have analgetic qualities (187).

Clinical studies have confirmed the safety of Curcumin. Thus, doses of up to 8.000mg/day are considered safe; above 10.000 mg several adverse effects, such as diarrhoea and yellow stools occur intermittently (188, 189). However, doses up to 12.000mg/day are not reported as toxic. The FDA (Food and Drug Administration) has approved the three main active ingredients of curcuma, curcumin, demethoxycurcumin and bisdemethoxycurcumin, available in different dosage forms as "Generally Recognized As Safe (GRAS)" (190). According to several in vitro studies, Curcumin has neither a negative effect on chromosomes nor does it have a mutagenic activity (191).

The majority of Curcumin's probable effects can be explained by its antioxidant and anti-inflammatory properties (184).

Curcumin enhances the serum activities of antioxidants such as SOD (superoxide dismutase), SOD catalase and lipid peroxides. Furthermore, Curcumin can inhibit various forms of free radicals, including reactive oxygen (ROS) and nitrogen species (RNS). ROS-producing enzymes such as cyclooxygenase, which play an important role in the development of PE, and lipoxygenase are effectively inhibited by Curcumin (192, 193).

Oxidative stress is closely associated to that of inflammation through similar pathological processes. Inflammatory cells release reactive species, which in turn lead to oxidative stress. ROS and RNS are capable of triggering intracellular signalling cascades that increase the expression of pro-inflammatory genes (186, 194).

Inflammation has been observed in many chronic diseases such as cardiovascular disease, metabolic syndrome, diabetes, obesity and arthritis (195). Curcumin lowers the raised levels of ROS, IL-6, TNF- α , and reduces COX-2 expression. It also significantly reduces the expression of proinflammatory cytokines (196, 197).

It is a known fact, that elevated levels of TNF-alpha play a significant role in mediating inflammation in PE as well as APS (198).

Inflammatory cytokines and various inflammatory stimuli activate both TNF- α and NF- κ B, a TNF- α regulators. Studies have shown that Curcumin is able to interact with TNF- α and NF- κ B and

might therefore have an important role in suppressing nuclear translocation of NF- κ B in rat vascular smooth muscle cells (186).

Furthermore, it has been shown that Curcumin could significantly attenuate anti- β 2GPI-induced tissue factor expression in aorta and peritoneal macrophages. Anti- β 2GPI was inhibited in vivo through the activation of NF- κ B signalling pathways. It might be speculated, that Curcumin minimizes the thrombogenic effects of anti- β 2GPI (199).

Curcumin has hardly been tested as a sole substance in mouse models in OAPS, rather in combination with vitamin D or fish oil in different concentrations (200).

3. Conclusion

Although PE is not the most prevalent obstetric complication in women with APS, its significance in prevention and management as well as regarding an expectable impact on further life for mother and child should not be underestimated, especially in cases of LOP, as these women have mostly an impaired pre-pregnancy cardiovascular or metabolic status.

According to several findings and theories, two considerations appear:

First, although the pathophysiologic similarities of APS and EOP are quite interesting, it is still obtuse why some women with APS develop early onset PE and some not.

Second, LOP in women with APS- according to the pathophysiology- may not be caused by aPI, but seems to be random and a "side effect". Additionally, there is still tenuous information regarding the incidence of LOP in women with APS in literature.

Spontaneous preterm delivery, mostly caused by premature rupture of fetal membranes seems to happen not only in rare cases in women with APS. This complication appears mostly by surprise. Regarding the- unfortunately not that seldom- severe consequences for the child, regular screening for premature rupture of fetal membranes as well as preterm delivery such as measurements of cervical length, should therefore be implemented in the management during pregnancy in women with APS.

As prior fetal loss seems to be an important risk factor for (spontaneous) preterm delivery, the knowledge of the medical history of previous pregnancies might improve the pregnancy outcome.

The gold standard treatment is still low dose aspirin (LDA; 100-150 mg/day) and low-molecular-weight-heparin (LMWH) in prophylactic dosage, starting as early as possible in pregnancy. However, the potential prophylactic use of LDA does only apply for EOP; LOP might be prevented by life-style modification prior conception.

Regarding OMAPS, NC-OAPS and SNAPS, there is still debate about the management during pregnancy.

Several additional treatment options for refractory APS have been proposed. However, to this day, only corticosteroids and HCQ are the most feasible therapy options for recurrent refractory cases, in relation to side effects, costs and practicality.

Nutritional interventions, such as intake of vitamin D have shown promising beneficial effects (30-34).

Although there are no real data and evidence for Curcumin supplementation in APS, respectively OAPS, certain effects Curcumin should not be underestimated.

References

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4(2):295-306.
2. ACOG Practice Bulletin No. 118: antiphospholipid syndrome. *Obstet Gynecol.* 2011;117(1):192-9.
3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. *Lancet.* 2010;376(9751):1498-509.
4. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. *J Autoimmun.* 2014;48-49:20-5.

5. Alijotas-Reig J, Esteve-Valverde E, Anunciación-Llunell A, Marques-Soares J, Pardos-Gea J, Miró-Mur F. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. *J Clin Med*. 2022;11(3).
6. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al. Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. *Rheumatology (Oxford)*. 2020;59(6):1306-14.
7. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. *Autoimmun Rev*. 2019;18(4):406-14.
8. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. *Arthritis Care Res (Hoboken)*. 2013;65(11):1869-73.
9. Page JM, Christiansen-Lindquist L, Thorsten V, Parker CB, Reddy UM, Dudley DJ, et al. Diagnostic Tests for Evaluation of Stillbirth: Results From the Stillbirth Collaborative Research Network. *Obstet Gynecol*. 2017;129(4):699-706.
10. Helgadóttir LB, Skjeldestad FE, Jacobsen AF, Sandset PM, Jacobsen EM. The association of antiphospholipid antibodies with intrauterine fetal death: a case-control study. *Thromb Res*. 2012;130(1):32-7.
11. Silver RM, Parker CB, Reddy UM, Goldenberg R, Coustan D, Dudley DJ, et al. Antiphospholipid antibodies in stillbirth. *Obstet Gynecol*. 2013;122(3):641-57.
12. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. *Ultrasound Obstet Gynecol*. 2020;56(2):298-312.
13. Miller SL, Huppi PS, Mallard C. The consequences of fetal growth restriction on brain structure and neurodevelopmental outcome. *J Physiol*. 2016;594(4):807-23.
14. Francis JH, Permezel M, Davey MA. Perinatal mortality by birthweight centile. *Aust N Z J Obstet Gynaecol*. 2014;54(4):354-9.
15. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. *Obstet Gynecol*. 2019;133(1):1.
16. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. *Hypertens Pregnancy*. 2003;22(2):143-8.
17. Practice Bulletin No. 171: Management of Preterm Labor. *Obstet Gynecol*. 2016;128(4):e155-64.
18. Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? *Curr Rheumatol Rep*. 2007;9(3):219-25.
19. Mayer-Pickel K, Stern C, Cervar-Zivkovic M, Schöll W, Moertl M. Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. *J Reprod Immunol*. 2020;138:103101.
20. Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. *Semin Arthritis Rheum*. 2011;41(3):517-23.
21. Le Thi Thuong D, Tieulie N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. *Ann Rheum Dis*. 2005;64(2):273-8.
22. Alsulyman OM, Castro MA, Zuckerman E, McGehee W, Goodwin TM. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. *Obstet Gynecol*. 1996;88(4 Pt 2):644-6.
23. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. *Obstet Gynecol*. 1989;73(4):541-5.
24. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. *Thromb Res*. 2004;114(5-6):419-26.
25. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. *Blood*. 2014;123(3):404-13.
26. Ruffatti A, Tonello M, Favaro M, Del Ross T, Calligaro A, Ruffatti AT, et al. The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. *Semin Arthritis Rheum*. 2021;51(1):28-35.

27. Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado MJ, Latino JO, et al. Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. *Thromb Haemost.* 2018;118(4):639-46.
28. Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Menegatti E, et al. Treatment of antiphospholipid syndrome. *Clin Immunol.* 2020;221:108597.
29. Alijotas-Reig J, Esteve-Valverde E, Llorba E, Gris JM. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. *Semin Arthritis Rheum.* 2019;49(2):314-8.
30. Andreoli L, Piantoni S, Dall'Ara F, Allegri F, Meroni PL, Tincani A. Vitamin D and antiphospholipid syndrome. *Lupus.* 2012;21(7):736-40.
31. Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. *Lupus.* 2020;29(12):1571-93.
32. Cyprian F, Lefkou E, Varoudi K, Girardi G. Immunomodulatory Effects of Vitamin D in Pregnancy and Beyond. *Front Immunol.* 2019;10:2739.
33. De Carolis S, Tabacco S, Rizzo F, Giannini A, Botta A, Salvi S, et al. Antiphospholipid syndrome: An update on risk factors for pregnancy outcome. *Autoimmun Rev.* 2018;17(10):956-66.
34. García-Carrasco M, Jiménez-Herrera EA, Gálvez-Romero JL, Mendoza-Pinto C, Méndez-Martínez S, Etchegaray-Morales I, et al. The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. *Lupus.* 2018;27(14):2181-9.
35. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy Hypertens.* 2014;4(2):97-104.
36. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. *Placenta.* 2009;30 Suppl A(Suppl A):S32-7.
37. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. *Am J Obstet Gynecol.* 1996;175(5):1365-70.
38. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. *Am J Obstet Gynecol.* 2013;209(6):544.e1-e12.
39. Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. *Lancet.* 1980;2(8190):366.
40. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. *Br Med J (Clin Res Ed).* 1983;287(6399):1088-9.
41. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. *N Engl J Med.* 1985;313(21):1322-6.
42. Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. *N Engl J Med.* 1985;313(3):152-6.
43. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. *Obstet Gynecol.* 1992;80(4):614-20.
44. Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. *Obstet Gynecol.* 1993;82(6):970-7.
45. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. *Clin Exp Rheumatol.* 1996;14(2):131-6.
46. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost.* 2012;38(4):305-21.
47. Meroni PL, Raschi E, Grossi C, Pregolato F, Trespidi L, Acaia B, et al. Obstetric and vascular APS: same autoantibodies but different diseases? *Lupus.* 2012;21(7):708-10.
48. D'Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. *Am J Reprod Immunol.* 2007;58(2):150-8.
49. Di Simone N, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. *Ann N Y Acad Sci.* 2007;1108:505-14.
50. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. *Annu Rev Pathol.* 2010;5:173-92.

51. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. *Bmj*. 2019;366:l2381.
52. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. *Placenta*. 2009;30 Suppl A:S38-42.
53. Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. *Am J Obstet Gynecol*. 2015;213(4 Suppl):S9.e1, S9-11.
54. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. *Lancet*. 1993;341(8858):1447-51.
55. McNally R, Alqudah A, Obradovic D, McClements L. Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling. *Curr Hypertens Rep*. 2017;19(11):93.
56. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? *Placenta*. 2014;35 Suppl:S20-5.
57. Tannetta D, Masliukaite I, Vatish M, Redman C, Sargent I. Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia. *J Reprod Immunol*. 2017;119:98-106.
58. Brosens I, Pijnenborg R, Vercruyse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. *Am J Obstet Gynecol*. 2011;204(3):193-201.
59. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia. *Am J Obstet Gynecol*. 2022;226(2s):S867-s75.
60. McLaughlin K, Zhang J, Lye SJ, Parker JD, Kingdom JC. Phenotypes of Pregnant Women Who Subsequently Develop Hypertension in Pregnancy. *J Am Heart Assoc*. 2018;7(14).
61. Pazner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. *Thromb Haemost*. 2001;86(6):1379-84.
62. Huong DL, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette JC. A study of 75 pregnancies in patients with antiphospholipid syndrome. *J Rheumatol*. 2001;28(9):2025-30.
63. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, Tincani A, Lefkou E, Bertero MT, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. *Autoimmun Rev*. 2015;14(5):387-95.
64. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum*. 2002;46(4):1019-27.
65. Cervera R. Antiphospholipid syndrome. *Thromb Res*. 2017;151 Suppl 1:S43-S7.
66. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *Bmj*. 2005;330(7491):565.
67. Katano K, Aoki A, Sasa H, Ogasawara M, Matsuura E, Yagami Y. beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. *Hum Reprod*. 1996;11(3):509-12.
68. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. *BMC Pregnancy Childbirth*. 2009;9:11.
69. van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, von Blomberg BM, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. *Am J Obstet Gynecol*. 1999;180(5):1146-50.
70. Yamamoto T, Yoshimura S, Geshi Y, Sasamori Y, Okinaga S, Kobayashi T, et al. Measurement of antiphospholipid antibody by ELISA using purified beta 2-glycoprotein I in preeclampsia. *Clin Exp Immunol*. 1993;94(1):196-200.
71. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. *Obstet Gynecol*. 1995;86(4 Pt 1):555-9.
72. Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. *Semin Thromb Hemost*. 2011;37(2):141-5.
73. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. *J Thromb Haemost*. 2016;14(4):675-84.
74. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramon E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis*. 2015;74(6):1011-8.

75. Yang J, Liang M. Risk factors for pregnancy morbidity in women with antiphospholipid syndrome. *J Reprod Immunol*. 2021;145:103315.
76. Deguchi M, Yamada H, Sugiura-Ogasawara M, Morikawa M, Fujita D, Miki A, et al. Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study. *J Reprod Immunol*. 2017;122:21-7.
77. Ye SL, Gu XK, Tao LY, Cong JM, Wang YQ. Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion. *Chin Med J (Engl)*. 2017;130(12):1395-9.
78. Saccone G, Berghella V, Maruotti GM, Ghi T, Rizzo G, Simonazzi G, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. *Am J Obstet Gynecol*. 2017;216(5):525 e1- e12.
79. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis*. 2009;68(9):1428-32.
80. Chaiworapongsa T, Romero R, Tarca A, Kusanovic JP, Mittal P, Kim SK, et al. A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. *J Matern Fetal Neonatal Med*. 2009;22(12):1122-39.
81. Salomon LJ, Diaz-Garcia C, Bernard JP, Ville Y. Reference range for cervical length throughout pregnancy: non-parametric LMS-based model applied to a large sample. *Ultrasound Obstet Gynecol*. 2009;33(4):459-64.
82. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. *N Engl J Med*. 1996;334(9):567-72.
83. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. *Lancet*. 2021;397(10280):1183-94.
84. Dodd JM, Grivell RM, CM OB, Dowswell T, Deussen AR. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. *Cochrane Database Syst Rev*. 2017;10(10):Cd012024.
85. Crowther CA, Ashwood P, McPhee AJ, Flenady V, Tran T, Dodd JM, et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. *PLoS Med*. 2017;14(9):e1002390.
86. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. *N Engl J Med*. 2003;348(24):2379-85.
87. Ashoush S, El-Kady O, Al-Hawwary G, Othman A. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. *Acta Obstet Gynecol Scand*. 2017;96(12):1460-6.
88. Saling E, Schumacher E. [Total surgical cervical occlusion. Conclusions from data of several clinica, which use total surgical cervical occlusion]. *Z Geburtshilfe Neonatol*. 1996;200(3):82-7.
89. Berghella V, Ciardulli A, Rust OA, To M, Otsuki K, Althuisius S, et al. Cerclage for sonographic short cervix in singleton gestations without prior spontaneous preterm birth: systematic review and meta-analysis of randomized controlled trials using individual patient-level data. *Ultrasound Obstet Gynecol*. 2017;50(5):569-77.
90. Berger R, Abele H, Bahlmann F, Doubek K, Felderhoff-Müser U, Fluhr H, et al. Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, September 2022) - Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and on the Management of Preterm Premature Rupture of Membranes. *Geburtshilfe Frauenheilkd*. 2023;83(5):569-601.
91. Berger R, Abele H, Bahlmann F, Doubek K, Felderhoff-Müser U, Fluhr H, et al. Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/025, September 2022) - Part 1 with Recommendations on the Epidemiology, Etiology, Prediction, Primary and Secondary Prevention of Preterm Birth. *Geburtshilfe Frauenheilkd*. 2023;83(5):547-68.
92. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, E LL, Ruffatti A, Tincani A, et al. Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. *Med Clin (Barc)*. 2018;151(6):215-22.
93. Conti F, Andreoli L, Crisafulli F, Mancuso S, Truglia S, Tektonidou MG. Does seronegative obstetric APS exist? "pro" and "cons". *Autoimmun Rev*. 2019;18(12):102407.

94. Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, et al. Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of "Non-criteria" Antiphospholipid Antibodies. *J Rheumatol*. 2017;44(11):1597-602.
95. Arachchillage DR, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. *Thromb Haemost*. 2015;113(1):13-9.
96. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. *Ann Rheum Dis*. 2003;62(12):1127.
97. Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. *Front Immunol*. 2018;9:2971.
98. Arabin B, Baschat AA. Pregnancy: An Underutilized Window of Opportunity to Improve Long-term Maternal and Infant Health-An Appeal for Continuous Family Care and Interdisciplinary Communication. *Front Pediatr*. 2017;5:69.
99. Epstein FH. LATE VASCULAR EFFECTS OF TOXEMIA OF PREGNANCY. *N Engl J Med*. 1964;271:391-5.
100. Hermes W, Franx A, van Pampus MG, Bloemenkamp KW, Bots ML, van der Post JA, et al. Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study. *Am J Obstet Gynecol*. 2013;208(6):474.e1-8.
101. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, et al. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. *Hypertension*. 2015;65(3):600-6.
102. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension*. 2011;57(1):85-93.
103. Kristensen JH, Basit S, Wohlfahrt J, Damholt MB, Boyd HA. Pre-eclampsia and risk of later kidney disease: nationwide cohort study. *Bmj*. 2019;365:l1516.
104. Prick BW, Bijlenga D, Jansen AJ, Boers KE, Scherjon SA, Koopmans CM, et al. Determinants of health-related quality of life in the postpartum period after obstetric complications. *Eur J Obstet Gynecol Reprod Biol*. 2015;185:88-95.
105. Blom EA, Jansen PW, Verhulst FC, Hofman A, Raat H, Jaddoe VW, et al. Perinatal complications increase the risk of postpartum depression. The Generation R Study. *Bjog*. 2010;117(11):1390-8.
106. Poel YH, Swinkels P, de Vries JI. Psychological treatment of women with psychological complaints after pre-eclampsia. *J Psychosom Obstet Gynaecol*. 2009;30(1):65-72.
107. Jacobsson B, Ahlin K, Francis A, Hagberg G, Hagberg H, Gardosi J. Cerebral palsy and restricted growth status at birth: population-based case-control study. *Bjog*. 2008;115(10):1250-5.
108. Paz I, Gale R, Laor A, Danon YL, Stevenson DK, Seidman DS. The cognitive outcome of full-term small for gestational age infants at late adolescence. *Obstet Gynecol*. 1995;85(3):452-6.
109. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, et al. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. *Bmj*. 1997;315(7105):396-400.
110. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA. Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years. *Bmj*. 1996;312(7028):406-10.
111. Law CM, de Swiet M, Osmond C, Fayers PM, Barker DJ, Cruddas AM, et al. Initiation of hypertension in utero and its amplification throughout life. *Bmj*. 1993;306(6869):24-7.
112. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. *Lancet*. 2021;398(10303):870-905.
113. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet*. 2008;371(9606):75-84.
114. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet*. 2008;371(9608):261-9.
115. Esteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J. Obstetric antiphospholipid syndrome. *Rev Clin Esp (Barc)*. 2016;216(3):135-45.
116. Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. *Lupus*. 2013;22(1):6-17.
117. Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. *Blood*. 2011;117(25):6948-51.

118. Sher G, Maassarani G, Zouves C, Feinman M, Sohn S, Matzner W, et al. The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid antibodies. *Am J Reprod Immunol.* 1998;39(4):223-5.
119. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. *Am J Obstet Gynecol.* 2000;182(1 Pt 1):122-7.
120. Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. *Autoimmun Rev.* 2016;15(3):226-35.
121. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. *Arthritis Rheum.* 2003;48(3):728-31.
122. Tincani A, Scarsi M, Franceschini F, Cattaneo R. Intravenous immunoglobulin in pregnancy: a chance for patients with an autoimmune disease. *Isr Med Assoc J.* 2007;9(7):553-4.
123. Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. *Hum Reprod.* 2002;17(3):809-16.
124. Dendrinou S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. *Int J Gynaecol Obstet.* 2009;104(3):223-5.
125. Urban ML, Bettiol A, Serena C, Comito C, Turrini I, Fruttuoso S, et al. Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature. *Autoimmun Rev.* 2020;19(9):102620.
126. Kaplan YC, Ozsarfaty J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. *Br J Clin Pharmacol.* 2016;81(5):835-48.
127. Mekinian A, Costedoat-Chalumeau N, Masseur A, Tincani A, De Caroli S, Alijotas-Reig J, et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? *Autoimmun Rev.* 2015;14(1):23-9.
128. Mekinian A, Cohen J, Alijotas-Reig J, Carbillon L, Nicaise-Roland P, Kayem G, et al. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? *Am J Reprod Immunol.* 2016;76(1):8-28.
129. Sciascia S, Branch DW, Levy RA, Middeldorp S, Pavord S, Roccatello D, et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. *Thromb Haemost.* 2016;115(2):285-90.
130. Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. *Autoimmun Rev.* 2015;14(6):498-502.
131. Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. *Autoimmun Rev.* 2018;17(12):1153-68.
132. Mekinian A, Vicaut E, Cohen J, Bornes M, Kayem G, Fain O. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. *Gynecol Obstet Fertil Senol.* 2018;46(7-8):598-604.
133. Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. *Semin Thromb Hemost.* 2017;43(6):562-71.
134. Ruffatti A, Favaro M, Hoxha A, Zambon A, Marson P, Del Ross T, et al. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. *J Reprod Immunol.* 2016;115:14-9.
135. Frampton G, Cameron JS, Thom M, Jones S, Raftery M. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. *Lancet.* 1987;2(8566):1023-4.
136. El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. *Int J Gynaecol Obstet.* 2007;99(3):236-41.

137. Costantine MM. Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. *J Clin Invest.* 2016;126(8):2792-4.
138. Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. *Hypertension.* 2014;63(5):e118-9.
139. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. *Clin Rev Allergy Immunol.* 2017;53(1):40-53.
140. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. *J Immunol.* 2005;174(1):485-90.
141. van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JJ. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. *Eur J Obstet Gynecol Reprod Biol.* 2016;197:168-73.
142. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. *Lancet.* 2014;384(9955):1673-83.
143. Mastrolia SA, Novack L, Thachil J, Rabinovich A, Pikovsky O, Klaitman V, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis. *Thromb Haemost.* 2016;116(5):868-78.
144. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Annals of the Rheumatic Diseases: BMJ Publishing Group;* 2019. p. 736-45.
145. Kerschbaumer A, Sepriano A, Smolen JS, Van Der Heijde D, Dougados M, Van Vollenhoven R, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases.* 2020.
146. Brito-Zerón P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. *Current Opinion in Rheumatology: Lippincott Williams and Wilkins;* 2014. p. 520-7.
147. Demarchi J, Papisidero S, Medina MA, Klajn D, Chaparro del Moral R, Rillo O, et al. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. *Clinical Rheumatology.* 2017;36(11):2455-60.
148. Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. *BMC Musculoskeletal Disorders.* 2017;18(1):186.
149. Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. *Expert Opin Drug Saf.* 2011;10(5):705-14.
150. Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. *Lupus Sci Med.* 2022;9(1).
151. Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. *Am J Obstet Gynecol.* 2016;214(2):273 e1- e8.
152. Gerde M, Ibarra E, Mac Kenzie R, Fernandez Suarez C, Heer C, Alvarez R, et al. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. *Thromb Res.* 2021;206:104-10.
153. Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. *Immunol Res.* 2017;65(1):17-24.
154. Kravvariti E, Koutsogianni A, Samoli E, Sfrikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. *Autoimmun Rev.* 2020;19(4):102491.
155. Palli E, Kravvariti E, Tektonidou MG. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. *Front Immunol.* 2019;10:487.
156. Do SC, Rizk NM, Druzin ML, Simard JF. Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? *Am J Perinatol.* 2020;37(9):873-80.

157. Hu Z, Gao R, Huang W, Wang H, Qin L. Effect of Hydroxychloroquine on Lupus Activity, Preeclampsia and Intrauterine Growth Restriction in Pregnant Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. *J Clin Med.* 2023;12(2).
158. Latino JO, Udry S, Aranda F, Wingeyer SP, Romero DSF, Belizna C, et al. Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. *Lupus.* 2020;29(13):1736-42.
159. Pasquier E, de Saint-Martin L, Marhic G, Chauleur C, Bohec C, Bretelle F, et al. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. *BMJ Open.* 2019;9(3):e025649.
160. Andreoli L, Bertias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Ann Rheum Dis.* 2017;76(3):476-85.
161. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. *Clin Rev Allergy Immunol.* 2013;45(2):217-26.
162. Aranow C. Vitamin D and the immune system. *J Investig Med.* 2011;59(6):881-6.
163. Rolf L, Muris AH, Hupperts R, Damoiseaux J. Vitamin D effects on B cell function in autoimmunity. *Ann N Y Acad Sci.* 2014;1317:84-91.
164. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J Immunol.* 2007;179(3):1634-47.
165. Morgan JW, Kouttab N, Ford D, Maizel AL. Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. *Endocrinology.* 2000;141(9):3225-34.
166. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. *Nutrients.* 2015;7(4):3011-21.
167. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. *J Clin Endocrinol Metab.* 1983;57(6):1308-10.
168. Marinho A, Carvalho C, Boleixa D, Bettencourt A, Leal B, Guimarães J, et al. Vitamin D supplementation effects on FoxP3 expression in T cells and FoxP3(+)/IL-17A ratio and clinical course in systemic lupus erythematosus patients: a study in a Portuguese cohort. *Immunol Res.* 2017;65(1):197-206.
169. Chen L, Eapen MS, Zosky GR. Vitamin D both facilitates and attenuates the cellular response to lipopolysaccharide. *Sci Rep.* 2017;7:45172.
170. Iruretagoyena M, Hirigoyen D, Naves R, Burgos PI. Immune Response Modulation by Vitamin D: Role in Systemic Lupus Erythematosus. *Front Immunol.* 2015;6:513.
171. Tetlow LC, Smith SJ, Mawer EB, Woolley DE. Vitamin D receptors in the rheumatoid lesion: expression by chondrocytes, macrophages, and synoviocytes. *Ann Rheum Dis.* 1999;58(2):118-21.
172. Piantoni S, Andreoli L, Scarsi M, Zanola A, Dall'Ara F, Pizzorni C, et al. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. *Lupus.* 2015;24(4-5):490-8.
173. Zhao M, Duan XH, Wu ZZ, Gao CC, Wang N, Zheng ZH. Severe vitamin D deficiency affects the expression of autophagy related genes in PBMCs and T-cell subsets in active systemic lupus erythematosus. *Am J Clin Exp Immunol.* 2017;6(4):43-51.
174. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *Jama.* 2006;296(23):2832-8.
175. Aivo J, Hänninen A, Ilonen J, Soilu-Hänninen M. Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. *J Neuroimmunol.* 2015;280:12-5.
176. Lee CL, Ng BK, Wu LL, Cheah FC, Othman H, Ismail NAM. Vitamin D deficiency in pregnancy at term: risk factors and pregnancy outcomes. *Horm Mol Biol Clin Investig.* 2017;31(3).
177. Fernández-Alonso AM, Dionis-Sánchez EC, Chedraui P, González-Salmerón MD, Pérez-López FR. First-trimester maternal serum 25-hydroxyvitamin D₃ status and pregnancy outcome. *Int J Gynaecol Obstet.* 2012;116(1):6-9.
178. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. *Ann Rheum Dis.* 2011;70(1):145-50.
179. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. *J Clin Endocrinol Metab.* 2007;92(9):3517-22.

180. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res.* 2003;23(1A):363-98.
181. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Res.* 2002;22(6C):4179-81.
182. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. *Biochem Biophys Res Commun.* 2005;326(2):472-4.
183. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. *Clin Cancer Res.* 2007;13(11):3423-30.
184. Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P. Curcumin and curcumin-like molecules: from spice to drugs. *Curr Med Chem.* 2014;21(2):204-22.
185. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol.* 2009;41(1):40-59.
186. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendía LE, Majeed M, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. *Biomed Pharmacother.* 2016;82:578-82.
187. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. *Inflammopharmacology.* 2017;25(1):25-31.
188. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med.* 2006;6:10.
189. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. *Molecules.* 2011;16(6):4567-98.
190. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J.* 2013;15(1):195-218.
191. Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Crit Rev Food Sci Nutr.* 2017;57(13):2889-95.
192. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. *Adv Exp Med Biol.* 2007;595:105-25.
193. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. *J Diet Suppl.* 2016;13(2):209-20.
194. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Altern Med Rev.* 2009;14(2):141-53.
195. Lopez-Candales A, Hernandez Burgos PM, Hernandez-Suarez DF, Harris D. Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. *J Nat Sci.* 2017;3(4).
196. Phumsuay R, Muangnoi C, Dasuni Wasana PW, Hasriadi, Vajragupta O, Rojsitthisak P, et al. Molecular Insight into the Anti-Inflammatory Effects of the Curcumin Ester Prodrug Curcumin Diglutamic Acid In Vitro and In Vivo. *Int J Mol Sci.* 2020;21(16).
197. Lestari ML, Indrayanto G. Curcumin. *Profiles Drug Subst Excip Relat Methodol.* 2014;39:113-204.
198. Vitoratos N, Economou E, Iavazzo C, Panoulis K, Creatsas G. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. *Mediators Inflamm.* 2010;2010:908649.
199. Xia L, Xie H, Yu Y, Zhou H, Wang T, Yan J. The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse. *PLoS One.* 2016;11(2):e0147958.
200. Maalouly G, Ward C, Smayra V, Saliba Y, Aftimos G, Haddad F, et al. Fish oil attenuates neurologic severity of antiphospholipid syndrome in a mice experimental model. *Nutr Neurosci.* 2017;20(10):563-70.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.